Galcanezumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Galcanezumab
Monoclonal antibody
Type Whole antibody
Source Human
Target CALCA, CALCB
Clinical data
Trade names Emgality
Synonyms LY2951742
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6392H9854N1686O2018S46
Molar mass 144.1 kDa

Galcanezumab, marketed under the trade name Emgality, is a humanized monoclonal antibody used for the prevention of migraine.[1][2] It is directed against calcitonin-related polypeptides alpha and beta.

This drug was developed by Eli Lilly & Co. As of July 2017.[3] The drug was approved by the US FDA in September 2018, becoming the third marketed CGRP inhibitor for the United States.[4]

See also[edit]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Galcanezumab, American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
  3. ^ H. Spreitzer (3 July 2017). "Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab". Österreichische Apothekerzeitung (in German) (14/2017).
  4. ^ "US FDA approves Lilly migraine drug at a price that is the same as its rivals". CNBC. Reuters. 28 September 2018. Retrieved 29 September 2018.